Human benign prostatic epithelial cells contain functional melatonin receptors that can suppress cell growth and viability. The development of benign prostatic hyperplasia in men is assumed to result from androgen-estrogen imbalance. These data indicate that 1) DHT and E 2 enhance prostate epithelial cells growth, but reduce cell growth when combined; 2) DHT extenuates the inhibitory effects of melatonin on epithelial cell growth; and 3) E 2 acts to inactivate melatonin receptors and consequently responses in human epithelial benign prostatic hyperplasia cells. This process is probably mediated by protein kinase C.
I]melatonin binding in these cells without affecting binding site density. In parallel, the ability of melatonin to suppress [ 3 H]thymidine incorporation into the cells was ablated within 1 h after the addition of E 2 . The melatonin-mediated increase in cAMP and decrease in cGMP concentrations were also ablated by E 2 .
Preincubation of the cells with bis-indolylmaleimide (GF 102903X), a specific inhibitor of protein kinase C, prevented the E 2 -mediated inactivation of melatonin binding and the inhibitory action on These data indicate that 1) DHT and E 2 enhance prostate epithelial cells growth, but reduce cell growth when combined; 2) DHT extenuates the inhibitory effects of melatonin on epithelial cell growth; and 3) E 2 acts to inactivate melatonin receptors and consequently responses in human epithelial benign prostatic hyperplasia cells. This process is probably mediated by protein kinase C.
Together, these results show an interplay between melatonin and sex steroids in the regulation of benign prostatic epithelial cell growth. (J Clin Endocrinol Metab 82: 2535-2541, 1997) B ENIGN PROSTATE hyperplasia (BPH) is a disease of men characterized by symptoms of urinary obstruction caused by abnormal, nonmalignant, prostate growth. The prevalence of BPH increases sharply in men over 50 yr of age (1) . Age-related changes in circulating concentrations of testosterone and estrogen, their balance, or their receptors in the prostate have been postulated to play a role in the development of BPH in man (2) (3) (4) . In dogs, induction of BPH required administration of both dihydrotestosterone (DHT) and 17␤-estradiol (E 2 ) (5). The presence of DHT and E 2 receptors was confirmed in BPH tissues (6) , although most of the E 2 receptors were located in stromal cells (7, 8) .
Melatonin, produced nocturnally by the pineal gland, plays a major role in the coordination of seasonal reproduction and pubertal development in mammals (9) . The production of melatonin declines with age (9 (11) . Melatonin at physiological concentrations inhibited DNA and protein synthesis in these cells and reduced their viability (11) .
In a number of studies, melatonin-binding sites in the brain as well as melatonin responses have been shown to depend on the presence of sex steroids. In the female rat hypothalamus and medulla-pons, ovariectomy produced a large estradiol-reversible decrease in low affinity [
125 I]melatonin-binding sites (12) . In parallel, the inhibitory effects of melatonin on dopamine release from the hypothalamus diminished in ovariectomized female rats and was reinstated by estradiol supplementation (13) . In male hamsters maintained in a long day environment, castration produced a large testosterone-reversible decrease in low affinity [ 125 I]melatonin-binding sites in the hypothalamus, medullapons, and hippocampus (14) . On the other hand, castration has been shown to increase the density of high affinity [ 125 I]melatonin-binding sites in the male rat anterior pituitary (15) . Castration also affected [
125 I]melatonin-binding sites in the Harderian gland of the golden hamster and blind mole rat (16, 17) . Thus, we explored the modulation by sex steroids of melatonin receptors and responses in human benign prostate epithelial cells. Besides inhibition of [ 3 H]thymidine incorporation (11), we found (unpublished) that melatonin increased cAMP and decreased cGMP in human benign prostate epithelial cells. Hence, we used the melatonin-mediated inhibition of thymidine incorporation, suppression of cGMP, and increase in cAMP levels as markers for melatonin responses in prostate epithelial cells.
Our results indicate E 2 -mediated inactivation of melatonin receptor binding and responses in prostate epithelial cells. We recently observed protein kinase C (PKC)-induced inactivation of melatonin receptors in these cells (unpublished). Nongenomic activation of PKC by E 2 has been reported in human uterine endometrium, rat ovary, and rat pituitary (18 -21) . Activation of PKC by androgens has also been reported in some studies (22) , but not in others (23, 24) . Human BPH tissue has been reported to contain phospholipid-dependent, phorbol 12-myristate 13-acetate (TPA)-activated, PKC isoforms (25) . Hence, in the present study we investigated the possibility that the effects of E 2 on melatonin receptors and responses in prostate epithelial cells were mediated by PKC. (26) .
Materials and Methods Materials
RPMI 1640 medium, RPMI 1640 medium without phenol red supplemented with l-glutamine (RPMI-P), newborn calf serum (NBS), charcoal-stripped NBS (NBSC), 0.05% insulin, transferrin, selenium, and antibiotics were obtained from Biological Industries (Beit Haemek, Israel).
Epithelial cell cultures
Human prostate tissue samples were obtained from patients undergoing elective transabdominal prostatectomies for BPH. All patients (aged 55-80 yr; n ϭ 21) were otherwise healthy. Approval for the use of the tissue was obtained from the local ethical committee. Epithelial cells were cultured as previously described (11) and grown at 37 C in growth medium (RPMI containing 10% NBS, 10 ng/mL epidermal growth factor, 5 ng/mL insulin, 5 ng/mL transferrin, 5 ng/mL selenium, 50 U/mL penicillin, 50 g/mL streptomycin, 250 ng/mL amphotericin B, and 10 ng/mL DHT) in a humidified atmosphere with 5% CO 2 . Before each experiment, cells were harvested by trypsin and adjusted to a density of 10 6 cells/mL in culture medium (RPMI containing 10% NBSC, 10 ng/mL epidermal growth factor, 5 ng/mL insulin, 5 ng/mL transferrin, 5 ng/mL selenium, 50 U/mL penicillin, 50 g/mL streptomycin, and 10 ng/mL DHT) and replated in 24-well multiplates. After 24 h, the culture medium was replaced with fresh culture medium containing 5% NBSC and used in the experiments. Protein content was determined in each plate (27) . As shown below (see Table 2 ) the ratio of protein per cell was constant under the experimental procedures employed. Hence, data from all experiments were normalized to protein content.
Sex steroid treatment
Cells attached to the plates were incubated with DHT, E 2 , or both (10 nmol/L unless otherwise stated) for 1 h to 4 days at 37 C. Melatonin responses and [
125 I]melatonin binding were then assessed. In some experiments, cells grown in the presence of DHT (10 nmol/L) were incubated with GF 102903X (500 nmol/L, 30 min at 37 C) or TPA (100 ng/mL, 18 h) before the addition of E 2 (10 nmol/L), and incubation was resumed for an additional 1-h period.
[ 125 I]Melatonin binding
Equilibrium binding studies were carried out as previously described (11) . Briefly, cells were incubated for 60 min at 37 C with 10 pmol/L and 1 nmol/L [ 125 I]melatonin (2000 Ci/mmol) in RPMI-P medium in the absence (total binding) or presence (nonspecific binding) of 2 mol/L melatonin. The media were then removed, and cells were immediately washed (twice, 2 mL each time) with ice-cold phosphate-buffered saline (PBS) and dissolved in 0.1 mol/L NaOH. Aliquots were collected for determination of protein content. The amount of radioactivity associated with the cells was determined in a ␥-counter.
The equilibrium binding data at the concentration range used were compatible with a single type of binding site (Scatchard analysis). The equilibrium binding parameters were obtained by nonlinear regression analysis of the binding data (Sigmaplot, Jandel Scientific, San Rafael, CA).
Thymidine incorporation
[ 3 H]Thymidine incorporation was assessed as previously described (11) . Briefly, cells attached to the plates were incubated with buffer or melatonin for 1 h at 37 C. [ 3 H]Thymidine (60 Ci/mmol; 1 Ci/well) was then added, and incubation was resumed for 1 h. Media were then discarded, and the cells were washed (twice, 2 mL each time) with ice-cold PBS and harvested by trypsin. Aliquots were retained for protein determination. Trichloroacetic acid was added, and insoluble materials were collected by filtration on GF/C glass fiber filters (Whatman, Clifton, NJ). The amount of radioactivity was determined by scintillation spectrometry.
Determination of cAMP and cGMP in cells
Cells were washed twice with PBS, harvested mechanically using a rubber policeman, and suspended in RPMI-P medium containing 200 mol/L phenylmethylsulfonylfluoride. Aliquots of the cell suspension were incubated for 10 min at 37 C with the phosphodiesterase inhibitor isobutylmethaxine (10 -6 mol/L). Melatonin (10 Ϫ10 -10 Ϫ6 mol/L) or the same volume of vehicle (0.01% ethanol in PBS) was then added, and incubation resumed for 10 min. The reaction mixture was then boiled for 4 min, frozen, thawed, sonicated, and centrifuged for 10 min (10,000 ϫ g). The supernatant was collected. The cGMP and cAMP contents in samples were determined by RIAs. Data were normalized to protein content.
Statistical analyses
Results were compared by ANOVA followed by Student's t tests for paired comparisons; significance was set at P Ͻ 0.050 (28) .
Results

Effects of E 2 on [ 125 I]melatonin binding
The (Fig. 1, b and c, and Table 1) .
Preincubation of the cells with GF 102903X (30 min) before treatment with E 2 (10 nmol/L, 60 min) prevented the E 2 -mediated decrease in the apparent affinity of [ 125 I]melatonin binding, but the apparent density of the sites significantly decreased (Fig. 1d and Table 1 Table 1 ) compared to the control value, but a higher affinity than that in cells treated with E 2 alone. Here, too, the apparent binding site density was not affected (Fig. 1e and Table 1 ).
Effects of sex steroids and melatonin on [ 3 H]thymidine incorporation
The effects of various concentrations of DHT and E 2 or their equimolar combinations on (Fig. 2a) , and its effects were extenuated in the presence of DHT (Fig. 2b) .
Similar treatment of the cells with E 2 (10 (Fig. 2c) . The maximal increase was observed with 10 Ϫ9 -10 Ϫ8 mol/L, and the effect was attenuated at higher E 2 concentrations. However, the inhibition by melatonin of [ 3 H]thymidine incorporation was significant only with 10 Ϫ9 mol/L E 2 and was ablated at higher (10 Ϫ8 -10 Ϫ6 mol/L) E 2 concentrations (Fig.  2c) .
Treatment of the cells with equimolar concentrations of DHT and E 2 paradoxically reduced [
3 H]thymidine incorporation by the cells in a concentration-dependent manner. No further suppression of [ 3 H]thymidine incorporation by melatonin was evident under these conditions (Fig. 2d) .
The incorporation of [ 3 H]thymidine into cells cultured with DHT (10
Ϫ8 mol/L) at various times after the addition of E 2 (10 Ϫ8 mol/L) was examined (Fig. 3) . E 2 significantly suppressed [
3 H]thymidine incorporation in the cells within 1 h of addition and ablated the inhibitory response to melatonin (1 nmol/L). [ 3 H]Thymidine incorporation by the cells remained low during the 4 days of E 2 treatment, and no further response to melatonin was observed (Fig. 3) . The effects of E 2 treatment on cell count and protein content are depicted in Table 2 . The decrease in [ 3 H]thymidine incorporation by the cells was followed by decreases in cell count and, concomitantly, protein content of the plates. A protein to cell count ratio of 4.7 g/10,000 cells was found in cells grown without DHT. This value did not significantly change in cells grown with DHT or in the course of E 2 treatment.
The effects of the PKC inhibitor GF 102903X (500 nmol/L, 30 min) or the PKC activator TPA (100 ng/mL, 18 h) on the responsiveness of control and E 2 -treated cells to melatonin were studied (Fig. 4) . In the control cells grown with DHT (10 nmol/L), melatonin (1 h) inhibited [ 3 H]thymidine incorporation by up to 50% in a concentration-dependent manner (half-maximal effect at 1 nmol/L; Fig. 4) . Treatment of the cells with E 2 (10 nmol/L, 1 h) abolished this effect of melatonin. Pretreatment of the cells with GF 102903X (30 min) before E 2 treatment (10 nmol/L, 1 h) enhanced [ 3 H]thymidine incorporation (i.e. by 150% compared to that in E 2 -treated cells and by 60% compared to that in control cells; Fig  4) . In parallel, pretreatment with GF 102903X prevented the E 2 -mediated loss of the melatonin response, and the melatonin-mediated inhibition of [ 3 H]thymidine incorporation was extenuated (Fig. 4) .
Prolonged (18- (Fig. 4) .
Effects of E 2 and melatonin on cAMP and cGMP concentrations
The impact of E 2 on the melatonin-mediated effects on cAMP and cGMP were investigated (Fig. 5) . In the control cells cultured with DHT (10 nmol/L), melatonin increased cAMP and reduced cGMP contents. These effects were concentration dependent with the 50% effect (IC 50 ) at 0.2 and 2 nmol/L melatonin for cAMP and cGMP levels, respectively (Fig. 5a) . Treatment of the cells with E 2 (10 nmol/L, 1 h) also enhanced cAMP and suppressed cGMP levels (Fig. 5b) . In the presence of E 2 , the effects of melatonin on cAMP and cGMP levels in the cells were abolished (Fig. 5b) .
Discussion
The data presented here reveal an interplay among DHT, estradiol, and melatonin in the regulation of benign prostate epithelial cell growth. DHT and E 2 enhance prostate epithelial cell growth, but reduce cell growth when combined. DHT attenuates the inhibitory effects of melatonin on epithelial cell growth, whereas E 2 acts to inactivate melatonin receptors and, consequently, responses in human epithelial BPH cells.
Of particular interest is the relationship between the effects of the sex steroid combinations on [ 3 H]thymidine incorporation and their effects on cAMP and cGMP levels in the cells. In the presence of equimolar concentrations of E 2 and DHT, [ 3 H]thymidine incorporation was suppressed, whereas cAMP was greatly increased, and cGMP was decreased. An increase in cAMP is frequently associated with E 2 activity in various tissues, including human and dog prostate (29) . Elevation of cAMP frequently causes cell growth arrest (30) . Hence, the inhibition of [ 3 H]thymidine incorporation by E 2 (as also by melatonin) in cells grown with DHT may be due to the increase in cellular cAMP levels.
On the other hand, the effects of E 2 on cGMP seem to be tissue specific. In rat uterus and human coronary arteries, E 2 increased cGMP content (31, 32) , whereas in human granulosa cells, cGMP production may be reduced or increased, depending on E 2 concentrations (33). PKC has been shown to inhibit the activity of guanylyl cyclase in NIH-3T3 cells and in the human renal cell line SK-NEP-1 (34, 35) . Hence, the decrease in cGMP may result from the E 2 -mediated activation of PKC in human benign prostate epithelial cells.
Notably, E 2 rapidly enhanced [ 3 H]thymidine incorporation in the presence of DHT in GF 102903X-pretreated cells, while suppressing the incorporation in GF 102903X-untreated cells. These data point to the possibility that E 2 may act to enhance prostate cell growth by some undefined mechanism, whereas a concomitant E 2 -mediated activation of PKC prevents this action. The effect of E 2 on benign prostate epithelial cells has not been explored. However, in organ cultures of the rat ventral prostate, pharmacological E 2 concentrations have been found to block the androgen-mediated activation of [ 3 H]thymidine incorporation into DNA in the epithelium, whereas E 2 alone increased the volume density of epithelium (36) . These data are in agreement with our interpretation. E 2 rapidly (within 1 h) inactivates melatonin binding and desensitizes prostate epithelial cells to melatonin. The desensitization encompassed three different melatonin responses in these cells, namely the inhibition of [ 3 H]thymidine incorporation, the suppression of cellular cGMP, and the enhancement of cAMP. The E 2 effect might be due to inactivation of melatonin receptors, as indicated by the marked decrease in apparent ligand binding affinity.
The ability of the PKC inhibitor GF 102903X to prevent the E 2 -mediated desensitization of melatonin receptors implies the involvement of PKC in this effect. This explanation is compatible with previous reports on the activation of PKC by E 2 in a number of tissues at the transcriptional and posttranscription levels (18 -21) . E 2 has recently been found to stimulate a rapid Ca 2ϩ influx in LNCaP human prostate cancer cells (37) . Preliminary data obtained in our laboratory (unpublished) indicate that E 2 induced a rapid and large increase in 45 Ca influx into human benign prostate epithelial cells. Hence, E 2 may activate PKC activity in these cells by enhancing intracellular Ca 2ϩ . It should be noted that human BPH tissue reportedly contains TPA-but not Ca 2ϩ -activated PKC isoforms (25) . Hence, in prostate epithelial cells, the effect of E 2 on melatonin receptors may be predominantly mediated by a PKC isoform(s) that is not directly regulated by Ca 2ϩ . The mechanism by which PKC mediates melatonin receptor desensitization is unknown. Uncoupling of receptor-G protein complexes has been shown to decrease binding affinity, but not site density, in some G protein-coupled receptors (38, 39) . It is thus reasonable to assume that a PKC phosphorylation site is located at or close to a site that participates in melatonin binding or in coupling of the receptor to a G protein.
Prolonged incubations (Ͼ4 h) with TPA have been repeatedly shown to cause down-regulation of PKC (40 -42) . However, the long term (18-h) pretreatment with TPA partially preserved the binding and responsiveness to melatonin in the E 2 -treated (1 h) cells. Hence, the effects of E 2 might be partially mediated via a PKC isoform that becomes downregulated by TPA. These conclusions should be regarded with caution due to the diminished (20% of the control value) [ 3 H]thymidine incorporation by the cells after the long term TPA treatment.
On the other hand, the responsiveness of prostate cells to melatonin (as evidenced by melatonin's effects on [ 3 H]thymidine incorporation, cAMP, and cGMP) did not resume upon prolonged incubation (4 days) with E 2 . Moreover, the apparent affinity of the binding sites was further reduced. These data are compatible with a role for a nondown-regulated PKC isoform in the E 2 -mediated inactivation of melatonin receptors. On the other hand, it is possible that besides activating PKC, E 2 also acts via genomic pathways to increase PKC expression. Future experiments will be aimed at exploring E 2 -sensitive PKC isoforms in the prostate epithelial cells.
As shown here, pretreatment of the cells with GF 102903X prevented the E 2 -mediated decrease in apparent binding affinity in the cells, but significantly reduced the density of the binding sites. A similar phenomenon was noted in our recent studies in cells maintained in charcoal-stripped medium. In the latter, pretreatment with GF 102903X prevented the decrease in apparent binding affinity provoked by short term (30-min) TPA treatment, but significantly reduced binding site density. In both experiments, the reduction of binding site density did not suppress melatonin efficacy. These data imply that, as with other hormone receptors, there are spare receptors for melatonin in the cells.
Taken together, the data presented here show that melatonin responses in human prostate epithelial cells depend on the prevailing hormonal state. Namely, DHT supports, whereas E 2 inactivates, melatonin receptor binding and responses. These data demonstrate a modulatory role for melatonin in the androgen-estrogen interplay in human prostate epithelium.
